NETINT Technologies Announces Partnership With Leading Light Technologies
5.11.2019 17:00:00 EET | Business Wire | Press release
NETINT Technologies, an innovator of computational storage and video processing SoC solutions today announced a business and sales distribution channel partnership with Leading Light Technologies (L2Tek), a European distributor of advanced hardware and software solutions for broadcast, professional video, IPTV surveillance and industrial imaging markets
This strategic partnership will give NETINT Technologies unprecedented access to Europe by leveraging L2Tek’s extensive access into multiple vertical markets. L2Tek will have sales and marketing activities of NETINT Technologies’ products across both the UK and continental Europe.
NETINT’s Codensity™ video transcoding technology features real-time, high quality, scalable transcoding for live video streaming, which is enabled by harnessing the inherent advantages of ASIC-based encoding with the scalability of NVMe cloud storage infrastructure. Each Codensity Video Transcoder module features ASIC-based H.264 AVC and H.265 HEVC video processing which enables high quality transcoding at up to 8K UHD resolution, at a lower price point compared to alternative transcoding architectures. Codensity Video Transcoder U.2 modules integrate with host servers as an NVMe-based device. This advanced architecture enables ultra-dense transcoding capacity within an NVMe server architecture.
“With the explosive growth of internet streaming video including OTT and SVOD services, new high-performance, ultra dense transcoding solutions are needed now more than ever,” said Mark Scott-South, Director of Sales at L2Tek. “NETINT’s Codensity Transcoders are packaged in a unique SSD form factor which enables simple integration into NVME server platforms. The performance, density and flexibility of NETINT’s Codensity solution will give our European clients the necessary tools to address their demanding encoding requirements into the foreseeable future.”
"NETINT is excited to be partnering with L2Tek,” said Randal Horne, Director of Global Sales, NETINT Technologies. “L2Tek’s technical expertise combined with their deep customer relationships gives us extensive access to the European market and the ability to introduce the benefits of Codensity video transcoding solutions.”
About Lead Light Technologies
Leading Light Technologies Ltd, trading as L2Tek, is a manufacturers’ representative and distributor specialising in electronics hardware, software and semiconductor IP for the broadcast, professional video, IPTV, surveillance and industrial imaging markets. In addition, the company offers design services based on extensive experience in these sectors.
L2Tek markets high performance semiconductors for image processing and related applications, FPGA IP, optical modules for video and telecom systems, power supplies, displays, single-board computers, and high-speed connectors and interconnect assemblies.
The company’s engineering services ensure that technical solutions are precisely tailored to individual requirements. For more information visit https://www.l2tek.co.uk/
About NETINT Technologies
NETINT Technologies is an innovator of computational storage and video processing SoC solutions. Its Codensity portfolio enables cloud data centers, edge computing companies, and content providers to deploy scalable high-performance applications, while minimizing their data storage and video processing costs. NETINT, founded by an experienced team of storage SoC veterans, is a Canadian venture-funded high-tech company with R&D facilities in Vancouver, Toronto and Shanghai, China. For more information, visit www.netint.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005143/en/
Contact information
Press:
Bob Fung
bob.fung@netint.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
